May 23, 2017 04:40 PM EDT
R&D

Hard charg­ing Neu­ro­crine hit with a sud­den set­back as Tourette study flops

John Carroll

Editor & Founder

Kevin Gor­man, CEO of Neu­ro­crine Bio­sciences, presents at a Jef­feries in­vestor con­fer­ence in 2013. bloomberg/via get­ty im­ages

Neu­ro­crine has been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

Leg­end to dou­ble Carvyk­ti pro­duc­tion as it tar­gets block­buster sta­tus 

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times